Pacylex Pharmaceuticals Reports Phase 1 Safety and Efficacy Results for Zelenirstat in Colorectal and other Cancers
Edmonton, Alberta, Canada January. 16, 2023. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company focused on the development of a new class of targeted therapies, N-myristoyltransferase inhibitors (NMTi) for the treatment of hematologic and solid tumor cancers. Today Pacylex announced that the results of its Phase 1 dose escalation safety and tolerability study for zelenirstat, an investiga